Clinical neurology and neurosurgery · 2026
Laser interstitial thermal therapy for intracranial dural-based lesions: A single center case series of 20 patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Knott Maxon V, Himic Vratko, Khalafallah Adham M, Lu Victor M, Shah Khushi H, Rivera Cameron A, Sass Emma R, Gersey Zachary C, Aaronson Daniel M, Ivan Michael E, Komotar Ricardo J, Shah Ashish H
Аннотация
PURPOSE: Laser interstitial thermal therapy (LITT) is a minimally invasive alternative to craniotomy for intracranial lesions in patients who are poor surgical candidates, but its role in treating dural-based lesions remains underexplored. This study evaluates the safety and feasibility of LITT for dural-based lesions.
METHODS: We retrospectively reviewed 431 LITT cases at our institution and identified 20 patients who underwent LITT for 22 dural-based lesions (two patients received double LITT for two separate lesions). Primary outcomes included postoperative complications, neurologic deficits, extent of ablation (EOA), and readmission. Secondary outcomes included progression-free survival (PFS) and overall survival (OS). Subgroup analysis was performed by pathology type (meningioma vs metastasis).
RESULTS: Among 20 patients (mean age: 67 years), meningiomas (50%, n = 10) and metastases (35%, n = 7) were the most common pathologies. Most lesions (85%) were recurrent; 50% of patients had multifocal disease. Two patients underwent dual-lesion ablation with separate trajectories during the same surgery. Median lesion volume was 4.5 cm³ (IQR 6.5); mean EOA was 119.2% (SD 37.9%). EOA was similar for metastases (127.3%, n = 8) and meningiomas (102.9%, n = 11; p = 0.155), despite significantly different volumes (2.7 cm³ vs. 6.9 cm³; p = 0.015). One patient experienced transient neurological deficit postoperative, however there were no neurosurgical readmissions. Recurrence occurred in 11 patients (55%; mean PFS: 524 days). OS for overall cohort was 707 days but differed significantly between pathology groups (p = 0.012).
CONCLUSION: LITT appears safe and feasible for treating dural-based lesions in select patients. Despite technical challenges, outcomes support further investigation into LITT's long term efficacy and optimization of ablation parameters.
METHODS: We retrospectively reviewed 431 LITT cases at our institution and identified 20 patients who underwent LITT for 22 dural-based lesions (two patients received double LITT for two separate lesions). Primary outcomes included postoperative complications, neurologic deficits, extent of ablation (EOA), and readmission. Secondary outcomes included progression-free survival (PFS) and overall survival (OS). Subgroup analysis was performed by pathology type (meningioma vs metastasis).
RESULTS: Among 20 patients (mean age: 67 years), meningiomas (50%, n = 10) and metastases (35%, n = 7) were the most common pathologies. Most lesions (85%) were recurrent; 50% of patients had multifocal disease. Two patients underwent dual-lesion ablation with separate trajectories during the same surgery. Median lesion volume was 4.5 cm³ (IQR 6.5); mean EOA was 119.2% (SD 37.9%). EOA was similar for metastases (127.3%, n = 8) and meningiomas (102.9%, n = 11; p = 0.155), despite significantly different volumes (2.7 cm³ vs. 6.9 cm³; p = 0.015). One patient experienced transient neurological deficit postoperative, however there were no neurosurgical readmissions. Recurrence occurred in 11 patients (55%; mean PFS: 524 days). OS for overall cohort was 707 days but differed significantly between pathology groups (p = 0.012).
CONCLUSION: LITT appears safe and feasible for treating dural-based lesions in select patients. Despite technical challenges, outcomes support further investigation into LITT's long term efficacy and optimization of ablation parameters.